Social Anxiety Disorder Clinical Trial
Official title:
Efficacy of an Attention Guidance VR Intervention for Social Anxiety Disorder
Verified date | December 2021 |
Source | University of Texas at Austin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Social anxiety disorder (SAD) is a prevalent mental health concern that impacts approximately 12% of the population. One mechanism thought to maintain SAD is avoidance of faces (i.e. avoidance of negative evaluative threat). However, research on attentional processes in SAD has been confined to paradigms presented on computer monitors. To investigate attentional processes in a more naturalistic way the investigators developed an immersive, 360º-video virtual reality environment using real actors, as part of a pilot study. Participants with a range of social anxiety symptoms (from none to severe) completed a 5-minute speech in this virtual reality environment while their eye movements were recorded. Results from the study showed that greater symptoms of social anxiety were associated with avoidance of looking at faces (i.e. fewer fixations on faces). While existing treatments for SAD are moderately effective, a large number of individuals do not experience meaningful reductions in their symptoms. The overarching goal of this project is inform future treatment research for SAD. The investigators will test a brief attention guidance intervention for SAD that specifically targets avoidance of faces as a potential mechanism maintaining the disorder. The proposed research will use the eye tracking hardware and naturalistic virtual reality environment from the pilot study. The investigators will also collect eye tracking data prior to the intervention in order to investigate potential heterogeneity in the attentional processes of SAD. The investigators will test the hypotheses that (a) the attention guidance intervention, compared to the control intervention, will result in a greater reduction in symptoms of social anxiety, and (b) this effect will be mediated by the number of fixations on faces during a brief public speaking challenge following the intervention. These results will provide causal evidence related to a hypothesized mechanism maintaining SAD.
Status | Terminated |
Enrollment | 21 |
Est. completion date | March 25, 2020 |
Est. primary completion date | March 11, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Age 18-65; 2. Fluent in English; 3. Personal Report of Public Speaking Anxiety score > 98; 4. Leibowitz Social Anxiety Scale > 30; 5. Peak fear = 50 on the behavioral approach task during the baseline assessment; 6. Meets DSM-5 Criteria for Social Anxiety Disorder. Exclusion Criteria: 1. Currently receiving CBT for Social Anxiety Disorder; 2. Significant visual impairment precluding the use of virtual reality equipment; 3. Unstable dose of psychotropic medications within 3 weeks prior to baseline assessment; 4. Current alcohol or substance use disorders; 5. Current, or history of bipolar disorder; current, or history of psychosis; 6. Serious suicidal risk, as determined by clinical interview. |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas at Austin | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Personal Report of Public Speaking Anxiety Scale Post-intervention | Questionnaire that assesses fear of public speaking Score range (total summed score): 34-170; Higher score reflects greater public speaking anxiety | Immediately following the end of the 1-week intervention | |
Primary | Personal Report of Public Speaking Anxiety Scale at 1-week | Questionnaire that assesses fear of public speaking Score range: 34-170 (total summed score); Higher score reflects greater public speaking anxiety | 1-week follow-up | |
Secondary | Leibowitz Social Anxiety Scale Post-intervention | Questionnaire that assesses generalized social anxiety Score range (total summed score): 0-144; Higher scores reflect greater social anxiety | Immediately following the end of the 1-week intervention | |
Secondary | Leibowitz Social Anxiety Scale at 1-week | Questionnaire that assesses generalized social anxiety Score range (total summed score): 0-144; Higher scores reflect greater social anxiety | 1-week follow-up | |
Secondary | Speech Anxiety Thoughts Inventory Post-intervention | Assesses cognitions associated with social anxiety Score range (total summed score): 23-115; Higher scores reflect greater severity | Immediately following the end of the 1-week intervention | |
Secondary | Speech Anxiety Thoughts Inventory at 1-week | Assesses cognitions associated with social anxiety Score range (total summed score): 23-115; Higher scores reflect greater severity | 1-week follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485615 -
An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia
|
Phase 2 | |
Completed |
NCT00773162 -
Flushing in Social Anxiety Disorder on Seroquel
|
Phase 3 |